Aghajani, A., Khakpourian, Z., Bakhthiarzadeh, S., Adibipour, F., Sadr, M., Coleman-Fuller, N., Jamaati, H. & Motaghinejad, M. (2023). Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis. TANAFFOS (Respiration), 22(2), 182-186.

Aghajani, A., Khakpourian, Z., Bakhthiarzadeh, S., Adibipour, F., Sadr, M., Coleman-Fuller, N., Jamaati, H., & Motaghinejad, M. "Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis", TANAFFOS (Respiration), 22, 2, 2023, 182-186.

Aghajani A., Khakpourian Z., Bakhthiarzadeh S., Adibipour F., Sadr M., Coleman-Fuller N., Jamaati H., Motaghinejad M. (2023). 'Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis', TANAFFOS (Respiration), 22(2), pp. 182-186.

A. Aghajani, Z. Khakpourian, S. Bakhthiarzadeh, F. Adibipour, M. Sadr, N. Coleman-Fuller, H. Jamaati & M. Motaghinejad, "Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis," TANAFFOS (Respiration), 22 2 (2023): 182-186,

Aghajani A., Khakpourian Z., Bakhthiarzadeh S., Adibipour F., Sadr M., Coleman-Fuller N., Jamaati H., Motaghinejad M. Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis. TANAFFOS (Respiration). 2023;22(2):182-186.